We thank Dr Mesker et al for their comments on our study, (Downey et al, 2014) recognising their significant work promoting the concept of using tumour-stroma ratio (TSR) to determine the outcome in cancer (Mesker et al, 2007, 2009; Courrech Stall et al, 2010, 2011; de Kruijf et al, 2011; Dekker et al, 2013; Huijbers et al, 2013).
None of our ER-positive cohort (118 female, 62 males; Downey et al, 2014) received neoadjuvant therapy of any type. Neoadjuvant treatment induces pathological changes in the tumour, hence would render samples unsuitable for TSR analysis. We were limited in the amount of information that could be supplied in a short communication, however univariate and multivariate outcomes were provided.
We found high stromal content was related to better survival across genders in ER-positive disease (Downey et al, 2014), contrasting data in triple-negative breast cancer (de Kruijf et al, 2011) and, as highlighted by Mesker et al, their own work on ER-positive cases (de Kruijf et al, 2011; Dekker et al, 2013). As breast cancer is heterogeneous, subtle differences in stromal biology may exist between breast cancer subtypes, potentially impacting on outcome. Notably, tubular carcinoma, a type of invasive breast ductal carcinoma with an abundant stroma (Figure 1), is almost always ER-positive and has a favourable prognosis (Rakha et al, 2010).
Methodological heterogeneity exists between sampling methods used to assess TSR. Two key issues stand out: (1) lack of standardisation in TSR measurement, (2) area of tissue selected for analysis. Our in-house computer algorithm method selects a 9 mm2 area of a digitally scanned H&E image (Downey et al, 2014). Recent related work assessed TSR manually in a single section from the most invasive tumour area (Gujam et al, 2014). Mesker et al favour assessment of the whole slide, even suggesting an evaluation of all available microscope slides. Although rigorous assessment is to be commended, this technique may have practical implications for histopathologists should TSR evaluation ever become routine. Alternative approaches should be considered, compared and validated.
We believe that there is much more to the stroma in dictating outcome, than simply its proportion in relation to tumour. There is a need to examine the cell types that coexist within tumour stroma, for example, fibroblasts and immune cells (Hanahan and Coussens, 2012); a recent issue of this journal showed that patients with a high TSR had significantly reduced inflammatory cell infiltrate within their stroma (Gujam et al, 2014). It remains possible that discrepancies observed between studies of TSR in breast cancer may be due in part to components of the stromal microenvironment.
Consistent with all emerging techniques it takes time for the ideal methodology to become accepted in the field. We respectfully suggest the best way to achieve this for TSR is through collaboration, comparing different techniques, using carefully selected sub groups of breast cancer and working towards reaching a consensus, taking account not only of the stroma but the cells within.
References
Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, Tollenaar RA, van Sandick JW (2011) Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Eur J Cancer 47: 375–382.
Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, Spitzer-Naaykens JM, Karsten T, Hartgrink HH, Mesker WE, Tollenaar RA (2010) The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 46: 720–728.
de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE (2011) Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 125: 687–696.
Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, Tollenaar RA, Mesker WE (2013) Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat 139: 371–379.
Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, Kulka J, Pollock S, Rajan SS, Thygesen HH, Hanby AM, Speirs V (2014) The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. Br J Cancer 110: 1744–1747.
Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC (2014) The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Br J Cancer 111: 157–165.
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309–322.
Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, Johnstone EC, Kerr DJ, Mesker WE (2013) The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 24: 179–185.
Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, Miranda NF, van Leeuwen KA, Morreau H, Szuhai K, Tollenaar RA, Tanke HJ (2009) Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 31: 169–178.
Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA (2007) The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 29: 387–398.
Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, Macmillan D, Blamey RW, Ellis IO (2010) Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 28: 99–104.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Downey, C., Simpkins, S., Holliday, D. et al. Reponse to: comment on, ‘Tumour-stroma ratio (TSR) in oestrogen-positive breast cancer patients’. Br J Cancer 112, 1833–1834 (2015). https://doi.org/10.1038/bjc.2014.571
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2014.571
This article is cited by
-
The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
Breast Cancer Research and Treatment (2019)